Stock Movers: Barclays, Novartis, WPP (Podcast)
Source: Bloomberg, 5:05 www.bloomberg.com #Stock #Movers #Barclays #Novartis #WPP #Podcast
Tag: Novartis
Novartis Profit, Sales Decline as Generic Competition Bites
Novartis AG reported profit below analysts’ estimates and an unexpected sales decline as some of its best-selling medicines were hard…
Lp(a) drugs from Novartis, Amgen and Eli Lilly aim to prevent heart attacks
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers…
Anthropic Trust Adds Novartis CEO to Board
Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors, making him the first pharmaceutical industry…
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
March 27 (Reuters) – Swiss drugmaker Novartis said on Friday it will buy California-based biotech company Excellergy in a deal…
Novartis to Acquire Excellergy in Deal Worth Up to $2 Billion
Novartis AG reached an agreement to pay as much as $2 billion to acquire biotech firm Excellergy Inc. www.bloomberg.com #Novartis…
Novartis, Genentech sue alleging illegal importation of prescription drug
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building in Basel, Switzerland, Sept. 9,…
U.S. deal could shield Pharma company Novartis from tariffs: CEO
Swiss pharmaceutical giant Novartis‘ CEO has said he “thinks” the company has an agreement with the U.S. to shield it…
Novartis CEO defends $12 billion deal for Avidity as ‘appropriate risk to take’
By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead…
Novartis has firepower for big M&A deals, says CEO
This photograph taken on October 30, 2022, shows the logo of the Swiss pharmaceutical and drug maker Novartis on a…